NCT06508489View on ClinicalTrials.gov

A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

August 8, 2025

Study Completion Date

August 8, 2025

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

SAR443579

Pharmaceutical form: Powder for solution for infusion Route of administration: intravenous infusion

DRUG

venetoclax

Pharmaceutical form :Film coated tablet Route of administration: oral

DRUG

azacitidine

Pharmaceutical form: Lyophilized powder for suspension for injection Route of administration: intravenous or subcutaneous

Trial Locations (7)

2500

Investigational Site Number : 0360002, Wollongong

3000

Investigational Site Number : 0360001, Melbourne

10467

Montefiore Medical Center - Moses Campus- Site Number : 8400004, The Bronx

43221

The Ohio State University Wexner Medical Center - Ohio State Outpatient Care Upper Arlington- Site Number : 8400001, Columbus

77030

The University of Texas MD Anderson Cancer Center- Site Number : 8400008, Houston

91010

City of Hope National Medical Center- Site Number : 8400003, Duarte

97239

Oregon Health and Science University- Site Number : 8400006, Portland

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06508489 - A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | Biotech Hunter | Biotech Hunter